| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infant, Newborn | 78 | 2024 | 1479 | 3.820 |
Why?
|
| Sepsis | 12 | 2024 | 102 | 2.460 |
Why?
|
| Hypoxia-Ischemia, Brain | 6 | 2024 | 21 | 2.320 |
Why?
|
| Hypothermia, Induced | 5 | 2024 | 17 | 2.160 |
Why?
|
| Asphyxia Neonatorum | 6 | 2023 | 11 | 1.800 |
Why?
|
| Humans | 90 | 2024 | 14537 | 1.730 |
Why?
|
| Anti-Bacterial Agents | 9 | 2024 | 293 | 1.690 |
Why?
|
| Neonatal Sepsis | 7 | 2024 | 29 | 1.620 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2019 | 21 | 1.450 |
Why?
|
| Infant Mortality | 13 | 2024 | 97 | 1.400 |
Why?
|
| Infant | 31 | 2024 | 2244 | 1.320 |
Why?
|
| Pregnancy | 29 | 2024 | 1862 | 1.250 |
Why?
|
| Streptococcus agalactiae | 8 | 2019 | 202 | 1.210 |
Why?
|
| Infant, Premature | 9 | 2023 | 56 | 1.210 |
Why?
|
| Cardiopulmonary Resuscitation | 9 | 2020 | 25 | 1.200 |
Why?
|
| Female | 47 | 2024 | 9103 | 1.150 |
Why?
|
| Retrospective Studies | 13 | 2024 | 799 | 1.120 |
Why?
|
| South Africa | 36 | 2024 | 7596 | 1.090 |
Why?
|
| Streptococcal Infections | 6 | 2019 | 184 | 1.060 |
Why?
|
| Brain Diseases | 2 | 2023 | 24 | 1.040 |
Why?
|
| Pregnancy Complications, Infectious | 9 | 2019 | 529 | 0.970 |
Why?
|
| Infant, Premature, Diseases | 3 | 2019 | 19 | 0.960 |
Why?
|
| Meconium Aspiration Syndrome | 4 | 2008 | 13 | 0.910 |
Why?
|
| Child Mortality | 4 | 2024 | 96 | 0.910 |
Why?
|
| Male | 28 | 2024 | 6754 | 0.890 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 12 | 0.880 |
Why?
|
| Cerebral Palsy | 1 | 2023 | 12 | 0.850 |
Why?
|
| Infant, Newborn, Diseases | 4 | 2022 | 73 | 0.830 |
Why?
|
| Suction | 4 | 2013 | 10 | 0.810 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 6 | 0.760 |
Why?
|
| Listeriosis | 1 | 2021 | 8 | 0.760 |
Why?
|
| Emergency Medical Services | 6 | 2020 | 29 | 0.760 |
Why?
|
| Perinatal Care | 2 | 2013 | 21 | 0.720 |
Why?
|
| Tuberculosis | 3 | 2017 | 543 | 0.670 |
Why?
|
| Hypothermia | 1 | 2019 | 3 | 0.670 |
Why?
|
| Pregnancy Complications | 2 | 2019 | 55 | 0.660 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 27 | 0.650 |
Why?
|
| Disease Outbreaks | 4 | 2023 | 111 | 0.640 |
Why?
|
| Isoniazid | 2 | 2017 | 110 | 0.640 |
Why?
|
| Nutritional Status | 1 | 2019 | 76 | 0.630 |
Why?
|
| Meconium | 3 | 2008 | 20 | 0.630 |
Why?
|
| Rifampin | 2 | 2017 | 197 | 0.610 |
Why?
|
| Developing Countries | 8 | 2021 | 400 | 0.600 |
Why?
|
| Infectious Disease Transmission, Vertical | 7 | 2017 | 472 | 0.590 |
Why?
|
| Birth Weight | 7 | 2024 | 80 | 0.580 |
Why?
|
| Prospective Studies | 10 | 2023 | 1160 | 0.560 |
Why?
|
| Angiotensin II | 3 | 2007 | 5 | 0.550 |
Why?
|
| Adult | 16 | 2022 | 5913 | 0.550 |
Why?
|
| Resuscitation | 4 | 2020 | 18 | 0.550 |
Why?
|
| Antitubercular Agents | 2 | 2017 | 322 | 0.550 |
Why?
|
| HIV Infections | 9 | 2019 | 5097 | 0.540 |
Why?
|
| Child | 15 | 2024 | 2242 | 0.540 |
Why?
|
| Maternal Exposure | 1 | 2016 | 14 | 0.530 |
Why?
|
| Respiration, Artificial | 10 | 2021 | 47 | 0.530 |
Why?
|
| Chemoprevention | 1 | 2016 | 33 | 0.530 |
Why?
|
| Thoracic Wall | 1 | 2015 | 2 | 0.510 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2015 | 2 | 0.510 |
Why?
|
| Dextrocardia | 1 | 2015 | 3 | 0.510 |
Why?
|
| Young Adult | 10 | 2019 | 2498 | 0.480 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2014 | 3 | 0.460 |
Why?
|
| Delivery, Obstetric | 3 | 2015 | 79 | 0.460 |
Why?
|
| Tertiary Care Centers | 4 | 2023 | 80 | 0.460 |
Why?
|
| Umbilical Cord | 1 | 2013 | 7 | 0.440 |
Why?
|
| Respiratory Rate | 1 | 2013 | 1 | 0.440 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2011 | 4 | 0.430 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2024 | 17 | 0.430 |
Why?
|
| Meningitis | 2 | 2023 | 26 | 0.410 |
Why?
|
| Infant, Low Birth Weight | 4 | 2017 | 35 | 0.410 |
Why?
|
| Prenatal Care | 3 | 2015 | 147 | 0.410 |
Why?
|
| Candida | 2 | 2023 | 24 | 0.400 |
Why?
|
| Communicable Diseases | 2 | 2023 | 62 | 0.390 |
Why?
|
| Gestational Age | 7 | 2024 | 80 | 0.390 |
Why?
|
| Bacterial Infections | 3 | 2023 | 54 | 0.380 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 96 | 0.380 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 56 | 0.380 |
Why?
|
| Cause of Death | 7 | 2024 | 221 | 0.380 |
Why?
|
| Child, Hospitalized | 2 | 2021 | 26 | 0.370 |
Why?
|
| Adolescent | 9 | 2021 | 2985 | 0.370 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 91 | 0.370 |
Why?
|
| Klebsiella pneumoniae | 4 | 2024 | 39 | 0.350 |
Why?
|
| Antibodies, Bacterial | 3 | 2015 | 153 | 0.340 |
Why?
|
| Radiography | 4 | 2015 | 80 | 0.330 |
Why?
|
| Thienamycins | 1 | 2009 | 6 | 0.330 |
Why?
|
| Arginine Vasopressin | 2 | 2008 | 2 | 0.330 |
Why?
|
| Klebsiella Infections | 1 | 2009 | 13 | 0.320 |
Why?
|
| Obstetric Labor Complications | 1 | 2009 | 25 | 0.320 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2008 | 2 | 0.320 |
Why?
|
| Carbapenems | 3 | 2024 | 17 | 0.320 |
Why?
|
| Pulmonary Surfactants | 2 | 2023 | 8 | 0.320 |
Why?
|
| Program Development | 2 | 2008 | 32 | 0.310 |
Why?
|
| Cohort Studies | 5 | 2023 | 967 | 0.300 |
Why?
|
| Risk Factors | 7 | 2014 | 1475 | 0.300 |
Why?
|
| Parturition | 1 | 2008 | 31 | 0.300 |
Why?
|
| Blood Pressure | 4 | 2008 | 317 | 0.300 |
Why?
|
| Infant Formula | 1 | 2007 | 5 | 0.300 |
Why?
|
| Incidence | 4 | 2024 | 685 | 0.300 |
Why?
|
| Probiotics | 1 | 2007 | 12 | 0.300 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2007 | 17 | 0.290 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 195 | 0.290 |
Why?
|
| Decision Making | 1 | 2008 | 53 | 0.290 |
Why?
|
| Maternal Mortality | 1 | 2008 | 58 | 0.290 |
Why?
|
| Renin | 1 | 2007 | 10 | 0.290 |
Why?
|
| Cardiovascular System | 1 | 2007 | 3 | 0.290 |
Why?
|
| Renin-Angiotensin System | 1 | 2007 | 12 | 0.280 |
Why?
|
| Health Priorities | 1 | 2008 | 62 | 0.280 |
Why?
|
| Weight Gain | 1 | 2007 | 77 | 0.280 |
Why?
|
| Life Support Care | 2 | 2020 | 10 | 0.280 |
Why?
|
| Child, Preschool | 8 | 2024 | 1748 | 0.280 |
Why?
|
| Gram-Negative Bacteria | 2 | 2024 | 15 | 0.280 |
Why?
|
| Hydrops Fetalis | 1 | 2006 | 3 | 0.280 |
Why?
|
| Parvoviridae Infections | 1 | 2006 | 4 | 0.280 |
Why?
|
| Peritonitis | 1 | 2006 | 5 | 0.280 |
Why?
|
| Parvovirus B19, Human | 1 | 2006 | 5 | 0.280 |
Why?
|
| Cross Infection | 2 | 2024 | 52 | 0.270 |
Why?
|
| Animals, Newborn | 4 | 2008 | 6 | 0.260 |
Why?
|
| Amniotic Fluid | 1 | 2006 | 13 | 0.260 |
Why?
|
| Bacteria | 3 | 2023 | 47 | 0.260 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2017 | 10 | 0.250 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 135 | 0.250 |
Why?
|
| Phenylephrine | 1 | 2005 | 3 | 0.250 |
Why?
|
| Hospitals, Public | 2 | 2021 | 45 | 0.250 |
Why?
|
| Heart Rate | 5 | 2020 | 32 | 0.240 |
Why?
|
| Perinatal Death | 2 | 2022 | 33 | 0.240 |
Why?
|
| Case-Control Studies | 5 | 2024 | 480 | 0.240 |
Why?
|
| Prevalence | 5 | 2023 | 1192 | 0.240 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 198 | 0.240 |
Why?
|
| Mothers | 3 | 2021 | 195 | 0.240 |
Why?
|
| Labor, Obstetric | 3 | 2014 | 44 | 0.230 |
Why?
|
| Alprostadil | 1 | 2004 | 3 | 0.230 |
Why?
|
| Hyperostosis | 1 | 2004 | 3 | 0.230 |
Why?
|
| Hospitals | 2 | 2023 | 103 | 0.230 |
Why?
|
| Child Health | 2 | 2024 | 77 | 0.230 |
Why?
|
| Heart Defects, Congenital | 1 | 2004 | 12 | 0.230 |
Why?
|
| Ampicillin | 2 | 2003 | 2 | 0.230 |
Why?
|
| Penicillins | 2 | 2003 | 25 | 0.230 |
Why?
|
| Standard of Care | 1 | 2024 | 30 | 0.220 |
Why?
|
| Infection Control | 2 | 2021 | 31 | 0.220 |
Why?
|
| Surface-Active Agents | 1 | 2023 | 4 | 0.220 |
Why?
|
| Advisory Committees | 2 | 2020 | 14 | 0.220 |
Why?
|
| Heart Arrest | 2 | 2015 | 9 | 0.220 |
Why?
|
| Hypoxia | 1 | 2023 | 12 | 0.220 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 231 | 0.220 |
Why?
|
| Body Temperature | 3 | 2019 | 7 | 0.210 |
Why?
|
| Placenta | 1 | 2023 | 44 | 0.210 |
Why?
|
| Emergency Treatment | 2 | 2020 | 13 | 0.210 |
Why?
|
| Asphyxia | 1 | 2023 | 5 | 0.210 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2019 | 10 | 0.210 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 21 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 127 | 0.210 |
Why?
|
| Blood Culture | 2 | 2021 | 11 | 0.210 |
Why?
|
| Hemorrhage | 2 | 2012 | 72 | 0.210 |
Why?
|
| Vagina | 3 | 2014 | 91 | 0.210 |
Why?
|
| Brain | 2 | 2022 | 53 | 0.200 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 30 | 0.200 |
Why?
|
| Time Factors | 3 | 2013 | 507 | 0.200 |
Why?
|
| Hemodynamics | 1 | 2002 | 32 | 0.200 |
Why?
|
| Stillbirth | 4 | 2024 | 83 | 0.200 |
Why?
|
| Neuroprotection | 1 | 2022 | 4 | 0.200 |
Why?
|
| Adrenal Gland Diseases | 1 | 2001 | 1 | 0.190 |
Why?
|
| Meningitis, Listeria | 1 | 2021 | 3 | 0.190 |
Why?
|
| Survival Analysis | 2 | 2014 | 149 | 0.190 |
Why?
|
| Candidemia | 1 | 2021 | 13 | 0.190 |
Why?
|
| Intensive Care, Neonatal | 1 | 2021 | 4 | 0.190 |
Why?
|
| Visitors to Patients | 1 | 2021 | 2 | 0.180 |
Why?
|
| Patient Isolation | 1 | 2021 | 5 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2021 | 27 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2021 | 66 | 0.180 |
Why?
|
| Guideline Adherence | 1 | 2021 | 43 | 0.180 |
Why?
|
| Health Resources | 1 | 2021 | 66 | 0.180 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2020 | 4 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 385 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 14 | 0.170 |
Why?
|
| Consensus | 2 | 2020 | 62 | 0.170 |
Why?
|
| Patient Acuity | 1 | 2019 | 18 | 0.170 |
Why?
|
| Mortality | 3 | 2017 | 104 | 0.170 |
Why?
|
| Fetal Blood | 1 | 2019 | 27 | 0.170 |
Why?
|
| Ureaplasma | 1 | 2019 | 4 | 0.160 |
Why?
|
| Vitamin D | 1 | 2019 | 41 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 188 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 57 | 0.160 |
Why?
|
| Animals | 4 | 2008 | 1081 | 0.160 |
Why?
|
| Age of Onset | 1 | 2019 | 32 | 0.160 |
Why?
|
| Seasons | 1 | 2019 | 154 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 279 | 0.160 |
Why?
|
| Polymyxins | 1 | 2018 | 1 | 0.160 |
Why?
|
| Acinetobacter Infections | 1 | 2018 | 4 | 0.160 |
Why?
|
| ROC Curve | 2 | 2024 | 51 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2019 | 105 | 0.160 |
Why?
|
| Bacterial Capsules | 2 | 2015 | 33 | 0.160 |
Why?
|
| Cesarean Section | 1 | 2019 | 87 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2009 | 21 | 0.150 |
Why?
|
| Nevirapine | 2 | 2017 | 146 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 266 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 237 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 37 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 59 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 71 | 0.140 |
Why?
|
| Anthropometry | 1 | 2017 | 102 | 0.130 |
Why?
|
| Sheep, Domestic | 2 | 2007 | 2 | 0.130 |
Why?
|
| Sheep | 3 | 2008 | 9 | 0.130 |
Why?
|
| Epinephrine | 3 | 2020 | 9 | 0.130 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2015 | 2 | 0.130 |
Why?
|
| Poland Syndrome | 1 | 2015 | 2 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 1422 | 0.130 |
Why?
|
| Puerperal Infection | 1 | 2015 | 1 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 21 | 0.120 |
Why?
|
| Emergencies | 2 | 2015 | 16 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2020 | 889 | 0.120 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2015 | 40 | 0.120 |
Why?
|
| Syphilis, Congenital | 2 | 2004 | 13 | 0.120 |
Why?
|
| Herpesvirus 2, Human | 1 | 2014 | 43 | 0.110 |
Why?
|
| Monitoring, Physiologic | 4 | 2015 | 25 | 0.110 |
Why?
|
| Herpes Genitalis | 1 | 2014 | 43 | 0.110 |
Why?
|
| Intubation, Intratracheal | 2 | 2019 | 9 | 0.110 |
Why?
|
| Income | 1 | 2013 | 85 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 2 | 2019 | 6 | 0.100 |
Why?
|
| Quality of Health Care | 2 | 2017 | 62 | 0.100 |
Why?
|
| Coinfection | 1 | 2015 | 276 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2012 | 64 | 0.100 |
Why?
|
| Survival Rate | 3 | 2020 | 96 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2011 | 12 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 27 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 34 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 55 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 30 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2012 | 57 | 0.090 |
Why?
|
| Autopsy | 2 | 2024 | 140 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 156 | 0.090 |
Why?
|
| Hospitals, University | 2 | 2023 | 16 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 17 | 0.090 |
Why?
|
| HIV-1 | 2 | 2017 | 1260 | 0.090 |
Why?
|
| Chlorhexidine | 1 | 2009 | 10 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 16 | 0.080 |
Why?
|
| Skin | 1 | 2009 | 38 | 0.080 |
Why?
|
| Piperacillin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Amikacin | 1 | 2009 | 7 | 0.080 |
Why?
|
| Klebsiella | 1 | 2009 | 6 | 0.080 |
Why?
|
| Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
|
| Anti-HIV Agents | 2 | 2017 | 1324 | 0.080 |
Why?
|
| beta-Lactam Resistance | 1 | 2009 | 5 | 0.080 |
Why?
|
| Confidentiality | 1 | 2009 | 13 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 26 | 0.080 |
Why?
|
| beta-Lactamases | 1 | 2009 | 23 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 133 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 563 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 43 | 0.080 |
Why?
|
| Global Health | 2 | 2020 | 193 | 0.080 |
Why?
|
| Perineum | 1 | 2008 | 5 | 0.080 |
Why?
|
| Oxygen | 1 | 2008 | 25 | 0.080 |
Why?
|
| Apgar Score | 2 | 2005 | 8 | 0.080 |
Why?
|
| Maternal Welfare | 1 | 2008 | 9 | 0.080 |
Why?
|
| Africa South of the Sahara | 2 | 2024 | 353 | 0.080 |
Why?
|
| Bifidobacterium | 1 | 2007 | 2 | 0.070 |
Why?
|
| Milk Proteins | 1 | 2007 | 2 | 0.070 |
Why?
|
| Blood Gas Analysis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 63 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 125 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Registries | 1 | 2008 | 91 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 59 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2007 | 272 | 0.070 |
Why?
|
| Calcinosis | 1 | 2006 | 11 | 0.070 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 4 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2020 | 325 | 0.060 |
Why?
|
| Sodium Chloride | 1 | 2006 | 16 | 0.060 |
Why?
|
| Amnion | 1 | 2006 | 19 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2006 | 85 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2005 | 1 | 0.060 |
Why?
|
| Risk | 2 | 2015 | 87 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2005 | 95 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2017 | 34 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 18 | 0.060 |
Why?
|
| Logistic Models | 1 | 2005 | 254 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 16 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2004 | 9 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 63 | 0.060 |
Why?
|
| Dyspnea | 1 | 2023 | 10 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 22 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2023 | 13 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2015 | 42 | 0.050 |
Why?
|
| Neurologic Examination | 1 | 2003 | 5 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2003 | 9 | 0.050 |
Why?
|
| Brain Injury, Chronic | 1 | 2003 | 3 | 0.050 |
Why?
|
| Infant Care | 2 | 2015 | 10 | 0.050 |
Why?
|
| Fever | 1 | 2003 | 26 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 54 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2003 | 24 | 0.050 |
Why?
|
| Hindlimb | 1 | 2002 | 1 | 0.050 |
Why?
|
| Injections, Intra-Arterial | 1 | 2002 | 1 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2002 | 2 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 8 | 0.050 |
Why?
|
| Femoral Artery | 1 | 2002 | 11 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2022 | 9 | 0.050 |
Why?
|
| Vascular Resistance | 1 | 2002 | 12 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2003 | 175 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 260 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 244 | 0.050 |
Why?
|
| Pneumonia | 1 | 2024 | 131 | 0.050 |
Why?
|
| Reference Values | 2 | 2017 | 64 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 137 | 0.050 |
Why?
|
| Head | 1 | 2022 | 8 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2001 | 2 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 253 | 0.050 |
Why?
|
| Candida tropicalis | 1 | 2021 | 2 | 0.050 |
Why?
|
| Candida glabrata | 1 | 2021 | 2 | 0.050 |
Why?
|
| Seizures | 1 | 2021 | 20 | 0.050 |
Why?
|
| Candida parapsilosis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 21 | 0.050 |
Why?
|
| Drug Resistance, Fungal | 1 | 2021 | 13 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2021 | 22 | 0.050 |
Why?
|
| Candida albicans | 1 | 2021 | 15 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2001 | 77 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2021 | 30 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 40 | 0.050 |
Why?
|
| Laryngeal Masks | 2 | 2010 | 2 | 0.050 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2010 | 5 | 0.050 |
Why?
|
| Breast Feeding | 2 | 2017 | 120 | 0.040 |
Why?
|
| Fluid Therapy | 2 | 2010 | 25 | 0.040 |
Why?
|
| China | 1 | 2020 | 21 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 40 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 57 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 26 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 435 | 0.040 |
Why?
|
| Poverty | 1 | 2021 | 152 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 2 | 0.040 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 3 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 239 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 231 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 38 | 0.040 |
Why?
|
| Polymyxin B | 1 | 2018 | 1 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.040 |
Why?
|
| Colistin | 1 | 2018 | 5 | 0.040 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2018 | 10 | 0.040 |
Why?
|
| Acinetobacter baumannii | 1 | 2018 | 11 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 37 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 4 | 0.040 |
Why?
|
| Heart Massage | 1 | 2015 | 1 | 0.030 |
Why?
|
| Incubators, Infant | 1 | 2015 | 1 | 0.030 |
Why?
|
| Brain Damage, Chronic | 1 | 2015 | 2 | 0.030 |
Why?
|
| Airway Management | 1 | 2015 | 2 | 0.030 |
Why?
|
| Delivery Rooms | 1 | 2015 | 3 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 21 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2015 | 10 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 12 | 0.030 |
Why?
|
| Serotyping | 1 | 2015 | 66 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
| Streptococcal Vaccines | 1 | 2015 | 47 | 0.030 |
Why?
|
| Aged | 1 | 2019 | 1740 | 0.030 |
Why?
|
| Virus Shedding | 1 | 2014 | 24 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 327 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 370 | 0.030 |
Why?
|
| South America | 1 | 2013 | 27 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 72 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2012 | 30 | 0.030 |
Why?
|
| Awards and Prizes | 1 | 2011 | 2 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 284 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2003 | 370 | 0.020 |
Why?
|
| Teaching | 1 | 2011 | 8 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2011 | 13 | 0.020 |
Why?
|
| Warfarin | 1 | 2012 | 19 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 112 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 74 | 0.020 |
Why?
|
| Communication Barriers | 1 | 2011 | 10 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 3601 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2011 | 49 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 106 | 0.020 |
Why?
|
| Homeostasis | 1 | 2008 | 9 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2008 | 11 | 0.020 |
Why?
|
| Growth | 1 | 2008 | 14 | 0.020 |
Why?
|
| Aging | 1 | 2008 | 109 | 0.020 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2004 | 7 | 0.010 |
Why?
|
| Gentamicins | 1 | 2003 | 2 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 27 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 31 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 37 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2003 | 22 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 56 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 245 | 0.010 |
Why?
|
| Trachea | 1 | 1998 | 3 | 0.010 |
Why?
|
| Nose | 1 | 1998 | 2 | 0.010 |
Why?
|
| Mouth | 1 | 1998 | 8 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 171 | 0.010 |
Why?
|
| Critical Care | 1 | 1998 | 52 | 0.010 |
Why?
|